Pronóstico del mercado de terapias contra el cáncer de mama en América del Norte hasta 2030 – Análisis regional – por terapia farmacológica [terapia farmacológica dirigida (abemaciclib, ado-trastuzumab emtansina, palbociclib, trastuzumab y otras terapias farmacológicas objetivo), terapia farmacológica hormonal (moduladores selectivos del receptor de estrógeno, inhibidores de la aromatasa) y reguladores negativos selectivos de los receptores de estrógeno), quimioterapia e inmunoterapia/terapia biológica], tipo de cáncer de mama (receptor hormonal, HER2+ y cáncer de mama triple negativo) y canal de distribución (farmacias hospitalarias, farmacias de farmacias y minoristas, y farmacias en línea )
El creciente uso de la medicina personalizada impulsa el mercado terapéutico del cáncer de mama en América del Norte
La medicina personalizada implica adaptar los planes de tratamiento a pacientes individuales en función de su composición genética, entre otros factores. Este enfoque permite tratamientos altamente específicos y eficaces, ya que considera las características únicas del cáncer de cada paciente. Los avances en genómica y diagnóstico molecular han hecho de la medicina personalizada una opción viable en el tratamiento del cáncer de mama. Los proveedores de atención médica pueden identificar mutaciones genéticas específicas o biomarcadores que impulsan el crecimiento del cáncer analizando el tumor de un paciente a nivel molecular. Luego, esta información se puede utilizar para seleccionar las opciones de tratamiento más adecuadas, como terapias dirigidas o inmunoterapias, que probablemente sean las más efectivas para ese paciente en particular. El uso de la medicina personalizada en la terapéutica del cáncer de mama tiene el potencial de mejorar significativamente los resultados de los pacientes. Por ejemplo, en febrero de 2022, investigadores de los NIH desarrollaron un enfoque de terapia personalizada contra el cáncer de mama, una forma experimental de inmunoterapia que utiliza células inmunitarias que combaten tumores de pacientes para tratar a aquellas con cáncer de mama metastásico, avanzando en la medicina personalizada.
Al proporcionar tratamientos personalizados a pacientes individuales, los proveedores de atención médica pueden aumentar la probabilidad de obtener resultados exitosos y reducir el riesgo de efectos secundarios innecesarios. Además de mejorar los resultados de los pacientes, la medicina personalizada también ofrece beneficios económicos. Al seleccionar tratamientos que tienen más probabilidades de ser efectivos, los proveedores de atención médica pueden reducir los costos de atención médica asociados con tratamientos ineficaces y evitar gastos innecesarios. A medida que avancen los avances en genómica y diagnóstico molecular, es probable que la medicina personalizada sea cada vez más accesible y se integre en los protocolos de tratamiento estándar en los próximos años. Por lo tanto, se prevé que el uso cada vez mayor de la medicina personalizada traerá nuevas tendencias de crecimiento en el mercado terapéutico del cáncer de mama en América del Norte.
Descripción general del mercado terapéutico contra el cáncer de mama en América del Norte
El mercado terapéutico contra el cáncer de mama en América del Norte está segmentado en EE. UU., Canadá y México; Estados Unidos tiene la mayor cuota de mercado en esta región. El crecimiento del mercado se atribuye principalmente a la región, que se espera que sea testigo de un crecimiento constante debido a factores como la creciente prevalencia del cáncer de mama y el aumento de las inversiones en I+D para desarrollar nuevos tratamientos. Además, un número creciente de actores del mercado están ampliando su presencia geográfica en los países de América del Norte.
Las mejoras en la tecnología y la investigación médica han provocado la creación de tratamientos innovadores que pueden mejorar los resultados de los pacientes. Varias grandes empresas farmacéuticas, entre ellas Pfizer, Novartis, Roche, AstraZeneca y Eli Lilly, dominan el mercado terapéutico para el cáncer de mama en Estados Unidos. Estas empresas realizan importantes inversiones en investigación y desarrollo para introducir en el mercado medicamentos novedosos y mejorados. Las regulaciones y políticas implementadas por el gobierno también afectan al mercado. Las agencias gubernamentales de la Administración de Alimentos y Medicamentos (FDA) aprueban nuevos medicamentos y terapias para el tratamiento del cáncer de mama. En los próximos años, se prevé que el mercado terapéutico para el cáncer de mama se expandirá aún más.
Ingresos del mercado de terapias contra el cáncer de mama de América del Norte y pronóstico hasta 2030 (millones de dólares estadounidenses)
Segmentación del mercado de terapias contra el cáncer de mama de América del Norte
El mercado de terapias contra el cáncer de mama de América del Norte está segmentado según el tratamiento farmacológico, el tipo de cáncer de mama y el canal de distribución.
Basado en la terapia farmacológica, el mercado terapéutico del cáncer de mama de América del Norte está segmentado en terapia farmacológica dirigida, terapia farmacológica hormonal, quimioterapia e inmunoterapia/terapia biológica. El segmento de terapia farmacológica dirigida tuvo una participación mayor en 2022. El segmento de terapia farmacológica dirigida se subsegmenta además en abemaciclib, ado-trastuzumab emtansina, palbociclib, trastuzumab y otras terapias farmacológicas dirigidas. Además, el segmento de la terapia con medicamentos hormonales se clasifica en moduladores selectivos de los receptores de estrógeno, inhibidores de la aromatasa y reguladores negativos selectivos de los receptores de estrógeno.
En términos de tipo de cáncer de mama, el mercado terapéutico del cáncer de mama de América del Norte está segmentado en receptor hormonal, HER2+ y cáncer de mama triple negativo. El segmento de receptores hormonales tuvo una participación mayor en 2022.
Por canal de distribución, el mercado terapéutico del cáncer de mama de América del Norte se segmenta en farmacias hospitalarias, farmacias minoristas y de farmacias, y farmacias en línea. El segmento de farmacias hospitalarias tuvo una participación mayor en 2022.
Según el país, el mercado terapéutico del cáncer de mama de América del Norte se clasifica en EE. UU., Canadá y México. Estados Unidos dominó el mercado de terapias contra el cáncer de mama en América del Norte en 2022.
Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Genentech Inc, Teva Pharmaceutical Industries Ltd y Amgen Inc son algunas de las empresas líderes que operan en el mercado terapéutico del cáncer de mama de América del Norte.
Table of Content
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
4.1 Key Market Drivers
4.1.1 Growing Burden of Breast Cancer
4.1.2 Launch of Several Diagnostics and Screening Programs
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis and Treatment
4.3 Key Market Opportunities
4.3.1 Increased Support from Government and Private Organizations
4.4 Key Future Trends
4.4.1 Increasing Use of Personalized Medicine
4.5 Impact Analysis:
5. Breast Cancer Therapeutics Market - North America Market Analysis
5.1 North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
6. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Drug Therapy
6.1 Overview
6.2 North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
6.3 Targeted Drug Therapy
6.3.1 Overview
6.3.2 Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3.2.1 North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy, 2020-2030 (US$ Million)
6.4 Hormonal Drug Therapy
6.4.1 Overview
6.4.2 Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4.2.1 North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy, 2020-2030 (US$ Million)
6.5 Chemotherapy
6.5.1 Overview
6.5.2 Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.6 Immunotherapy/ Biological Therapy
6.6.1 Overview
6.6.2 Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Breast Cancer Type
7.1 Overview
7.2 North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
7.3 Hormone Receptor
7.3.1 Overview
7.3.2 Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 HER2+ (human epidermal growth factor receptor 2)
7.4.1 Overview
7.4.2 HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Triple-Negative Breast Cancer
7.5.1 Overview
7.5.2 Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 - by Distribution Channel
8.1 Overview
8.2 North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
8.3 Hospital Pharmacies
8.3.1 Overview
8.3.2 Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Drug Store and Retail Pharmacies
8.4.1 Overview
8.4.2 Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Online Pharmacies
8.5.1 Overview
8.5.2 Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. North America Breast Cancer Therapeutics Market - Regional Analysis
9.1 North America Breast Cancer Therapeutics Market, Revenue and Forecast To 2030
9.1.1 Overview
9.1.2 North America Breast Cancer Therapeutics Market, Breakdown, by Country, Revenue (2022) (US$ Million)
9.1.3 North America Breast Cancer Therapeutics Market, by Country
9.1.3.1 US
9.1.3.1.1 US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.1.2 US: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.1 US: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.2.2 US: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.1.3 US: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.1.4 US: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.2 Canada
9.1.3.2.1 Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.2.2 Canada: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.1 Canada: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.2.2 Canada: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.2.3 Canada: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.2.4 Canada: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
9.1.3.3 Mexico
9.1.3.3.1 Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
9.1.3.3.2 Mexico: Breast Cancer Therapeutics Market, by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.1 Mexico: Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.2.2 Mexico: Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy, 2020-2030 (US$ Million)
9.1.3.3.3 Mexico: Breast Cancer Therapeutics Market, by Breast Cancer Type, 2020-2030 (US$ Million)
9.1.3.3.4 Mexico: Breast Cancer Therapeutics Market, by Distribution Channel, 2020-2030 (US$ Million)
10. Breast Cancer Therapeutics Market-Industry Landscape
10.1 Overview
10.2 Growth Strategies in Breast Cancer Therapeutics Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 Eli Lilly and Co
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Eisai Co Ltd
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 Novartis AG
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 AstraZeneca Plc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Products and Services
11.4.4 Financial Overview
11.4.5 SWOT Analysis
11.4.6 Key Developments
11.5 Pfizer Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Gilead Sciences Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Merck & Co Inc
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Teva Pharmaceutical Industries Ltd
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 Amgen Inc
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Amgen Inc
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 About Us
12.2 Glossary of Terms
List of Tables
Table 1. North America Breast Cancer Therapeutics Market Segmentation
Table 2. North America Breast Cancer Therapeutics Market, by Targeted Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 3. North America Breast Cancer Therapeutics Market, by Hormonal Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 4. US Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 5. US Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 6. US Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 7. US Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 8. US Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 9. Canada Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 10. Canada Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 11. Canada Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 12. Canada Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 13. Canada Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 14. Mexico Breast Cancer Therapeutics Market, by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 15. Mexico Breast Cancer Therapeutics Market, For Targeted Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 16. Mexico Breast Cancer Therapeutics Market, For Hormonal Drug Therapy by Drug Therapy - Revenue and Forecast to 2030 (US$ Million)
Table 17. Mexico Breast Cancer Therapeutics Market, by Breast Cancer Type - Revenue and Forecast to 2030 (US$ Million)
Table 18. Mexico Breast Cancer Therapeutics Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
Table 19. Recent Organic Growth Strategies in Breast Cancer Therapeutics Market
Table 20. Recent Inorganic Growth Strategies in the Breast Cancer Therapeutics Market
Table 21. Glossary of Terms, Breast Cancer Therapeutics Market
List of Figures
Figure 1. North America Breast Cancer Therapeutics Market Segmentation, By Country
Figure 2. North America Breast Cancer Therapeutics Market - Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. North America Breast Cancer Therapeutics Market Revenue (US$ Mn), 2022 - 2030
Figure 5. North America Breast Cancer Therapeutics Market Revenue Share, by Drug Therapy, 2022 & 2030 (%)
Figure 6. Targeted Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Hormonal Drug Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Chemotherapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Immunotherapy/ Biological Therapy: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 10. North America Breast Cancer Therapeutics Market Revenue Share, by Breast Cancer Type, 2022 & 2030 (%)
Figure 11. Hormone Receptor: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. HER2+: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Triple-Negative Breast Cancer: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. North America Breast Cancer Therapeutics Market Revenue Share, by Distribution Channel, 2022 & 2030 (%)
Figure 15. Hospital Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Drug Store and Retail Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Online Pharmacies: North America Breast Cancer Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. North America Breast Cancer Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 19. North America Breast Cancer Therapeutics Market, By Key Countries, 2022 and 2030 (%)
Figure 20. US Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 21. Canada Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 22. Mexico Breast Cancer Therapeutics Market Revenue and Forecast to 2030 (US$ Mn)
Figure 23. Growth Strategies in Breast Cancer Therapeutics Market
1. Eli Lilly and Co
2. Eisai Co Ltd
3. Novartis AG
4. AstraZeneca Plc
5. Pfizer Inc
6. Gilead Sciences Inc
7. Merck & Co Inc
8. Genentech Inc
9. Teva Pharmaceutical Industries Ltd
10. Amgen Inc
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America breast cancer therapeutics market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in North America breast cancer therapeutics market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth North America market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution